Abstracts tagged "Epidemiology"

Abstract Number: 0754 • ACR Convergence 2025
Is There a Seasonal Pattern in Giant Cell Arteritis? Revisiting the Evidence in a Large Monocentric Cohort of 1203 patients
Milena Bond¹, Philipp Bosch², Aaron Juche³, Hans Bastian³ and Wolfgang Schmidt⁴, ¹South Tyrol Health Trust and Teaching Hospital of the Paracelsus Medical University, Brunico, Italy, ²Medical University of Graz, Graz, Austria, ³Rheumaklinik Berlin-Buch, Berlin, Germany, ⁴Immanuel Krankenhaus Berlin, Medical Centre for Rheumatology Berlin-Buch; Waldfriede Hospital, Rheumatology, Berlin, Germany
Background/Purpose: Whether the disease onset in giant cell arteritis (GCA) exhibits a seasonal pattern remains unclear. Previous studies have yielded conflicting evidence: some report no…
Abstract Number: 0325 • ACR Convergence 2025
Knee Symptom Phenotyping Incorporating Pain and Function across Different Levels of WOMAC Function in Two Cohorts: Data from the Multicenter Osteoarthritis Study (MOST) and the Osteoarthritis Initiative (OAI)
C. Kent Kwoh¹, Amanda Nelson², Rongrong Tang³, Edward J. Bedrick³, Yong Ge¹, Yvonne Golightly⁴, Zong-Ming Li³, Jean Liew⁵, Xiaoxiao Sun¹, Jeffrey Duryea⁶ and Tuhina Neogi⁵, ¹The University of Arizona Arthritis Center, University of Arizona, Tucson, AZ, ²University of North Carolina at Chapel Hill, Chapel Hill, NC, ³The University of Arizona Arthritis Center, University of Arizona, Tucson, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵Boston University School of Medicine, Boston, MA, ⁶Brigham and Women’s Hospital, Boston, MA
Background/Purpose: Knee pain and functional limitations are the most common symptoms of knee OA. Understanding the various patterns of symptoms (i.e., pain and function changes…
Abstract Number: 0145 • ACR Convergence 2025
Population Assessment of Cancer Incidence among Patients with Idiopathic Inflammatory Myopathies in North Carolina
Astia Allenzara¹, Ben Albright², Xi Zhou², Amanda Nelson³, Laura Green⁴, Katherine Reeder-Hayes⁴, Jennifer Lund⁴, Caroline Thompson⁴ and Chris Baggett⁴, ¹UNC, Chapel Hill, NC, ²University of North Carolina, Chapel Hill, NC, ³University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁴University of North Carolina, Chapel Hill
Background/Purpose: Cancer is highly prevalent and a leading cause of death for patients with Idiopathic Inflammatory Myopathies (IIM). Evaluating cancer type and stage at diagnosis…
Abstract Number: 2553 • ACR Convergence 2025
Impact of Polypharmacy on Treatment Adherence and Its Effect on The Quality of Life in Patients with Rheumatic Diseases
Egla Samantha Sanchez-Peralta¹, Margarita Isabel Alarcon-Jarquin², Vanessa L. Lopez-Flores², Dionicio A. Galarza-Delgado³ and Diana E. Flores-Alvarado¹, ¹Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México, Monterrey, Nuevo Leon, Mexico, ²Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico, ³Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico
Background/Purpose: Treatment adherence is fundamental for adequate control of rheumatic diseases. Nevertheless, due to the chronic nature of these conditions, polypharmacy can impact treatment adherence,…
Abstract Number: 1995 • ACR Convergence 2025
The Prevalence of Multimorbidity and Polypharmacy Among US Adults with Gout: A General Population-Based Study
Chio Yokose¹, Natalie McCormick², Jiaqi Wang², Sharan Rai³, leo lu⁴ and Hyon K. Choi⁵, ¹Massachusetts General Hospital, Waltham, MA, ²Massachusetts General Hospital, Boston, ³Massachusetts General Hospital/Harvard Medical School, Boston, MA, ⁴Arthritis Research Canada, Vancouver, BC, Canada, ⁵MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA
Background/Purpose: Gout is an inflammatory-metabolic condition that is associated with a heavy burden of cardiovascular-kidney-metabolic (CKM) comorbidities. Accordingly, multimorbidity and polypharmacy are important considerations which…
Abstract Number: 1890 • ACR Convergence 2025
Quantifying the Inflammatory Toll: Smoking-Attributable Rheumatoid Arthritis Burden Across the Globe, 1990–2021
Eva Kalra¹, Shreyaa Rajpal², Twisha Parikh³, Drumadala Gajbhiye⁴, Chethan Raj Gundoji⁵, Sagar Patel⁶, Jay Patel⁷, Neelima Sinha⁸, Nikhil Rayarakula⁹, Dhwani Vaghani¹⁰ and Hardik Dineshbhai Desai¹¹, ¹Trident Medical Center, North Charleston, SC, ²Osmania Medical College, Hyderabad, Telangana, India-⁵⁰⁰⁰⁹⁵, Hyderabad, India, ³GMERS Medical College and Hospital, Gotri, Vadodara, India ³⁹⁰⁰²¹, Vadodara, India, ⁴Government medical college Akola Maharashtra India ⁴⁴⁴⁰⁰¹, Akola, India, ⁵Internal Medicine, Government Medical College Nizamabad, Nizamabad, Telangana, India, ⁵⁰³⁰⁰¹, Nizamabad, India, ⁶Internal medicine -Ward Wizard Medicare Pvt Ltd, Nadiad, Gujarat, India, ³⁸⁷⁰⁰², Nadiad, India, ⁷MGM Medical College, Aurangabad, Maharashtra, India-⁴³¹⁰⁰³, Aurangabad, India, ⁸Department of Medicine, Kurji Holy Family Hospital, Patna, Bihar, India, ⁸⁰⁰⁰¹⁰, Patna, India, ⁹College of Public Health, Kent State University, Kent,Ohio, USA, ⁴⁴²⁴²., Kent, OH, ¹⁰Internal Medicine, MGM Medical College, Aurangabad, Maharashtra, India,⁴³¹⁰⁰³, Aurangabad, India, ¹¹Ahmedabad, Gujarat, India, ³⁸²³⁵⁰, Ahmedabad, India
Background/Purpose: Rheumatoid arthritis (RA), a chronic systemic inflammatory disorder, imposes a significant global health burden. Smoking is a well-established modifiable risk factor implicated in both…
Abstract Number: 1621 • ACR Convergence 2025
Temporal Association Between Viral Positivity Rates and Kawasaki Disease Incidence at a Large Tertiary Center
Jessica Nguyen¹, Duc Nguyen¹, Ankona Banerjee², Kenneth Nobleza², Denver Niles² and Marietta De Guzman¹, ¹Baylor College of Medicine, Houston, TX, ²Baylor College of Medicine, Houston
Background/Purpose: Kawasaki disease (KD) is a systemic vasculitis associated with the development of coronary artery aneurysms predominantly affecting children less than 5 years of age.…
Abstract Number: 1320 • ACR Convergence 2025
Trends In Incidence and Risk factors For Incident Venous Thromboembolism in Patients with Rheumatoid Arthritis: A Population-Based Retrospective Cohort Study
Noah Frechette¹, Elena myasoedova¹, Iqra Javed¹, Roslin George¹, Sara Achenbach² and Cynthia Crowson³, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, ³Mayo Clinic, Stewartvillle, MN
Background/Purpose: Venous thromboembolism (VTE) is more common in patients with rheumatoid arthritis (RA) and can present as deep vein thrombosis (DVT) or pulmonary embolism (PE).…
Abstract Number: 1024 • ACR Convergence 2025
Mortality In Progressive Pulmonary Fibrosis Associated to Autoimmune Diseases: NEREA Registry
Marta Ruiz-Valdepeñas Almansa¹, CLARA DE MIGUEL², DALIFER FREITES³, Cristina Vadillo Font⁴, Maria asuncion Nieto⁴, Olga Sanchez Pernaute⁵, fredeswinda Romero-Bueno⁶, Mª Jesus Rodriguez-Nieto⁷, Rosalia Laporta⁸, Hilda Godoy Tundidor⁹, Jesús Loarce¹⁰, Juan A Rigual¹¹ and lydia Abasolo Alcazar¹², ¹HOSPITAL CLINICO SAN CARLOS, Madrid, Spain, ²HOSPITAL CLINICO SAN CARLOS, Madrid, Madrid, Spain, ³Rheumatology Service, San Carlos Clinical Hospital, Madrid, Madrid, Spain, ⁴Hospital Clínico S Carlos, Madrid, Spain, ⁵Clinica Universidad de Navarra, Madrid, Madrid, Spain, ⁶University Hospital Fundación Jiménez Díaz"", Madrid, Spain, ⁷Fundacion Jimenez Diaz (IIS-HUFJD), Madrid, Spain, ⁸Hospital Puerta de Hierro Majadahonda, Madrid, Spain, ⁹Hospital Universitario puerta de hierro, Madrid, Spain, ¹⁰HOSPITAL RAMÓN Y CAJAL, MADRID, Madrid, Spain, ¹¹Hospital Ramón y Cajal, Madrid, Spain, ¹²IdISSC. HCSC, Madrid, Madrid, Spain
Background/Purpose: Autoimmune interstitial lung disease (ILD) may arise in various autoimmune rheumatic diseases (ARD). Some patients develop ILD with systemic symptoms and autoantibodies without fulfilling…
Abstract Number: 0745 • ACR Convergence 2025
Prevalence and Clinical Significance of Low ESR and CRP in Giant Cell Arteritis: A Population Based Study
Eugenio de Miguel, Natalia López-Juanes, Maria-Eugenia Miranda-Carus, Carlota Ureta, Chamaida Plasencia-Rodríguez and Irene Monjo Henry, Hospital Universitario La Paz, Madrid, Spain
Background/Purpose: Traditionally, elevated erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) had been considered a hallmark of GCA and both are included in the 2022…
Abstract Number: 0324 • ACR Convergence 2025
Bile Acids Metabolism in Symptomatic Hand Osteoarthritis: Data from the Xiangya Osteoarthritis Study and Genetics of OA Consortium
Jiatian Li¹, Jing Ye¹, Tuo Yang¹, david Hunter², Weiya Zhang³, Michael Doherty³, Yuqing Zhang⁴, Zidan Yang¹, Hui Li¹, Yilun Wang¹, Dongxing Xie¹, Ziying Wu⁵, Wei Li¹, Zeqin Wen¹, Changjun Li¹, Chao Zeng¹, Guanghua Lei¹ and Jie Wei¹, ¹Xiangya Hospital, Central South University, Changsha, Hunan, China (People's Republic), ²Sydney Musculoskeletal Health, University of Sydney, St Leonards, New South Wales, Australia, ³School of Medicine, University of Nottingham, Nottingham, United Kingdom, ⁴Massachusetts General Hospital, Quincy, MA, ⁵Xiangya Hospital, Central South University, Chang Sha, China (People's Republic)
Background/Purpose: Although gut microbiome dysbiosis has been implicated in symptomatic hand OA (SHOA), the potential contribution of bile acids (BAs), key metabolites in host-microbiota interactions,…
Abstract Number: 0037 • ACR Convergence 2025
A Proteomic Signature Containing TNF Receptor Superfamily Member 10A (TNFRSF10A) and Growth/Differentiation Factor 15 (GDF-15) Improves Prediction of All-Cause Mortality Among Individuals with Gout, Beyond Atherosclerotic Cardiovascular and Other Clinical Risk Factors
Natalie McCormick¹, Sharan Rai², Chio Yokose³, Tony Merriman⁴, Robert Terkeltaub⁵ and Hyon K. Choi⁶, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital/Harvard Medical School, Boston, MA, ³Massachusetts General Hospital, Waltham, MA, ⁴University of Alabama at Birmingham, Homewood, AL, ⁵Retired, San Diego, CA, ⁶MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA
Background/Purpose: Gout affects >12 million US adults and is associated with premature all-cause and cardiovascular (CV) mortality which has failed to improve over recent decades,…
Abstract Number: 2545 • ACR Convergence 2025
Prevalence, Clinical Correlations and Outcomes of Cryoglobulinemic Vasculitis: a Retrospective Monocentric Study (2013–2023)
Valeria Manfrè¹, elena treppo², Maria Pillon³, Maria De Martino⁴, Cinzia Fabro⁵, Miriam Isola⁴, Martina Fabris⁶, Francesco Curcio⁶ and Luca Quartuccio¹, ¹Division of Rheumatology, Department of Medicine (DMED), Academic Hospital "Santa Maria della Misericordia", ASUFC, University of Udine, Udine, Italy, Udine, Italy, ²Division of Rheumatology, Department of Medicine, University of Udine, Udine, Italy, ³Division of Rheumatology, Department of Medicine, University of Udine, Udine, Italy, Udine, Italy, ⁴Institute of Statistics, Department of Medicine, University of Udine, Udine, Italy., Udine, Italy, ⁵Division of Rheumatology, Department of Medicine, University of Udine, Udine, Italy., Udine, Italy, ⁶Institute of Clinical Pathology, Department of Medicine, University of Udine, Udine, Italy., Udine, Italy
Background/Purpose: Cryoglobulinemic vasculitis (CryoVas) is a rare immune-complex-mediated disorder, often associated with hepatitis C virus (HCV) infection, autoimmune diseases (ADs), or other etiologies. Despite its…
Abstract Number: 1925 • ACR Convergence 2025
Associations between Representation and Quality in Clinical Trials for Systemic Lupus Erythematosus
Joshua Skydel¹, Anna Leland², Reshma Ramachandran³, Fotios Koumpouras³ and Joshua Wallach², ¹Yale-New Haven Hospital, New Haven, CT, ²Rollins School of Public Health, Atlanta, GA, ³Yale School of Medicine, New Haven, CT
Background/Purpose: Drug development in SLE is informed by US Food and Drug Administration recommendations for study design, enrollment, and efficacy endpoints. However, persistent challenges to…
Abstract Number: 1887 • ACR Convergence 2025
Incidence, Prevalence and Mortality of Systemic Lupus Erythematosus – A 20-year territory-wide analysis of electronic health records in Hong Kong
Danting zhang¹, jiaxin S. Wu¹ and Desmond Yat-Hin Yap², ¹The University of Hong Kong, Hong Kong, Hong Kong, ²Department of Medicine, The University of Hong Kong, Hong Kong SAR, Hong Kong
Background/Purpose: Advancements in immunosuppressive treatments and general medical care in the past two decades have influenced the disease burden and outcomes of patients with systemic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].